PMID- 35398114
OWN - NLM
STAT- MEDLINE
DCOM- 20220523
LR  - 20220622
IS  - 1873-7528 (Electronic)
IS  - 0149-7634 (Linking)
VI  - 137
DP  - 2022 Jun
TI  - Glucose-lowering drugs, cognition, and dementia: The clinical evidence.
PG  - 104654
LID - S0149-7634(22)00143-9 [pii]
LID - 10.1016/j.neubiorev.2022.104654 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is an important risk factor for dementia. The 
      possibility to mitigate this risk by controlling T2DM is compelling; however, 
      different glucose-lowering drugs have different effects on the brain by virtue of 
      their different mechanisms of action. The clinical and epidemiological data 
      appear mixed, warranting careful critical evaluation of the human studies. Here 
      we examine the evidence in the context of dementia prevention and treatment, both 
      for people with and without T2DM. We discuss the evidence on this scaffold of 
      research directions, identifying methodological complexities in the extant 
      literature (e.g. comparator discrepancies, changes in the therapeutic landscape), 
      and the implications of different outcome measures (e.g. neuropsychological). We 
      consider possible implications of cerebrovascular protection vs. effects on 
      progression of neurodegenerative proteinopathy, and we present a research roadmap 
      for glucose-lowering drugs in cognitive neurology, including neuroimaging, and 
      fluid biomarkers. We conclude that there is great potential to advance 
      personalized strategies to prevent and treat dementia with glucose-lowering 
      drugs.
CI  - Copyright (c) 2022 Elsevier Ltd. All rights reserved.
FAU - Wu, Che-Yuan
AU  - Wu CY
AD  - Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, 
      Canada; Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain 
      Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
FAU - Shapiro, Lila
AU  - Shapiro L
AD  - Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, 
      Canada; Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain 
      Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
FAU - Ouk, Michael
AU  - Ouk M
AD  - Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, 
      Canada; Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain 
      Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
FAU - MacIntosh, Bradley J
AU  - MacIntosh BJ
AD  - Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences 
      Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of 
      Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Canadian 
      Partnership for Stroke Recovery, Sunnybrook Research Institute, Toronto, Ontario, 
      Canada.
FAU - Black, Sandra E
AU  - Black SE
AD  - Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences 
      Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Canadian 
      Partnership for Stroke Recovery, Sunnybrook Research Institute, Toronto, Ontario, 
      Canada; Department of Medicine, Division of Neurology, University of Toronto, 
      Toronto, Ontario, Canada; Toronto Dementia Research Alliance, Toronto, Ontario, 
      Canada.
FAU - Shah, Baiju R
AU  - Shah BR
AD  - ICES, Toronto, Ontario, Canada; Divisions of Endocrinology and Obstetric 
      Medicine, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, 
      Ontario, Canada.
FAU - Swardfager, Walter
AU  - Swardfager W
AD  - Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, 
      Canada; Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain 
      Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; 
      Canadian Partnership for Stroke Recovery, Sunnybrook Research Institute, Toronto, 
      Ontario, Canada; KITE UHN Toronto Rehabilitation Institute, Toronto, Ontario, 
      Canada.
LA  - eng
GR  - PJT-159711/CIHR/Canada
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220406
PL  - United States
TA  - Neurosci Biobehav Rev
JT  - Neuroscience and biobehavioral reviews
JID - 7806090
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Cognition
MH  - *Dementia/drug therapy
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - *Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Glucose
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/therapeutic use
MH  - *Metformin/therapeutic use
OTO - NOTNLM
OT  - Cognition
OT  - Dementia
OT  - Diabetes mellitus
OT  - Dipeptidyl peptidase-4 inhibitors
OT  - Epidemiology
OT  - Glucagon-like peptide-1 analogues
OT  - Insulin
OT  - Metformin
OT  - Sodium-glucose cotransporter-2 inhibitors
OT  - Sulfonylureas
OT  - Thiazolidinediones
EDAT- 2022/04/11 06:00
MHDA- 2022/05/24 06:00
CRDT- 2022/04/10 20:23
PHST- 2022/02/01 00:00 [received]
PHST- 2022/04/01 00:00 [revised]
PHST- 2022/04/03 00:00 [accepted]
PHST- 2022/04/11 06:00 [pubmed]
PHST- 2022/05/24 06:00 [medline]
PHST- 2022/04/10 20:23 [entrez]
AID - S0149-7634(22)00143-9 [pii]
AID - 10.1016/j.neubiorev.2022.104654 [doi]
PST - ppublish
SO  - Neurosci Biobehav Rev. 2022 Jun;137:104654. doi: 10.1016/j.neubiorev.2022.104654. 
      Epub 2022 Apr 6.